300 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Investor Presentation
Annual Meeting Results: Election of Class II Directors - Sujay Kango, Anne Mc...
Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Annual Report to Security Holders
Other Events
Dianthus Therapeutics Enters Underwriting Agreement for $593.5M Offering
Material disclosure
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities